Top US FDA Drug Policy Leader Leaving For White House Detail
Grail Sipes, CDER deputy center director for regulatory policy, will move to the Executive Office of the President next month.
You may also be interested in...
The Center for Drug Evaluation and Research’s policy guru must think about the future, along with the present, in her position as director of the Office of Regulatory Policy.
Juliana Reed, who just moved from Pfizer to head the trade group, hopes scientific advances will eventually eliminate the need for the interchangeability designation, but for now the association is educating stakeholders in preparation for the 2023 launch of Humira biosimilars.
Republican opposition to Califf over the agency’s recent move to relax its Mifeprex restrictions is ominous since in order be confirmed as FDA commissioner he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to the drug industry.